Less Ads, More Data, More Tools Register for FREE

Pin to quick picksE2V.L Regulatory News (E2V)

  • There is currently no data for E2V

Contract Win

20 Nov 2008 07:00

RNS Number : 5213I
e2v technologies PLC
20 November 2008
 



20 November  2008 

e2v technologies plc

Contract Win 

e2v technologies, a specialist developer and manufacturer of high technology components and sub-systems, announces an £11m contract renewal to supply Varian Medical Systems, Inc., headquartered in Palo Alto, US, with electron devices for incorporation into linear accelerators, for use in radiotherapy cancer treatment and cargo screening systems.

The contract will be worth at least £11m (payments will be in US dollars at the prevailing exchange rate) over two years, and is the first of a number of anticipated multi-year contract renewals for electron devices used in linear accelerators. e2v's products generate and deliver the microwave power required from the linear accelerator to produce X-rays used in both the imaging and radiation treatment of tumours as well as the imaging systems within cargo screening equipment.

This contract represents an increase in business with this customer, has the potential to increase in value over the term of the agreement, and is in line with management's growth expectations for this sector.

Keith Attwood, Chief Executive of e2v said: ``This multi-year contract renewal with Varian is a demonstration of the strong and close relationships we build with our strategic partners.''

For further information:

e2v technologies plc

Tel: +44 (0)1245 493493

Keith Attwood/Mike Hannant

www.e2v.com

Financial Dynamics

Tel: +44 (0)20 7269 7225

Jon Simmons/Sophie Kernon

   

NOTES FOR EDITORS

e2v 

e2v's objective is to be a global leader in the design and supply of specialised components and sub-systems that enable the world's leading systems companies to deliver innovative solutions for medical and science, aerospace and defence, and commercial and industrial markets.

e2v has 4 major product groups:

High performance electron devices and subsystems for applications including defence electronic countermeasures, radiotherapy cancer treatment, and radar systems

Advanced Imaging sensors and cameras for applications including industrial process control, dental X-ray systems, space science and life sciences

Specialist semiconductors, including logic, memory and microprocessors for high reliability mission-critical programs in avionics, defence and telecommunications, sensor data acquisition, and high speed data conversion

A range of professional sensing products for applications including fire, rescue and security thermal imaging, X-ray spectroscopy, and military surveillance, targeting and guidance

For the year ended 31 March 2008, e2v achieved sales of £205m and is listed on the London Stock Exchange. In October 2008 e2v acquired QP semiconductor, a leading US-based designer and supplier of specialty semiconductor components used in military and aerospace applications, establishing e2v's first US manufacturing base. 

The Company is headquartered in the United Kingdom and has approximately 1800 employees in six production facilities across Europe and North America. e2v also operates a global network of sales and technical support offices, supported by local distributors and resellers.

Further information is available from www.e2v.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTFKCKDABDDFDD
Date   Source Headline
3rd Jan 20144:37 pmRNSHolding(s) in Company
5th Dec 201311:42 amRNSAdditional Listing
27th Nov 201311:35 amRNSGeneral Meeting
19th Nov 20134:25 pmRNSNOTIFICATION OF MAJOR INTEREST IN SHARES
14th Nov 20133:27 pmRNSNotification of Major Interest in Shares
14th Nov 201312:49 pmRNSNotice of General Meeting
6th Nov 20134:57 pmRNSTransaction in Own Shares
4th Nov 201311:44 amRNSDirector/PDMR Shareholding
4th Nov 20137:00 amRNSHalf-year results for six months to 30 Sept 2013
18th Oct 20137:00 amRNSAppointment of Chief Executive
15th Oct 20137:00 amRNSPeriod end update
14th Oct 20134:15 pmRNSHolding(s) in Company
1st Oct 20134:51 pmRNSTransaction in Own Shares
27th Sep 20134:18 pmRNSPurchase of Own Shares
23rd Sep 20134:00 pmRNSShare buy-back programme
19th Aug 20132:15 pmRNSTotal Voting Rights
13th Aug 20134:15 pmRNSHolding(s) in Company
13th Aug 20131:30 pmRNSDirector/PDMR Shareholding
23rd Jul 20137:00 amRNSDirector/PDMR Shareholding
19th Jul 20137:00 amRNSAwards under Long Term Incentive Plan
17th Jul 20131:45 pmRNSAnnual General Meeting 2013
17th Jul 20137:00 amRNSDirectorate Change
17th Jul 20137:00 amRNSInterim Management Statement
1st Jul 20134:35 pmRNSHolding(s) in Company
26th Jun 20134:29 pmRNSHolding(s) in Company
26th Jun 201311:11 amRNSHolding(s) in Company
12th Jun 201312:00 pmRNSDirectorate Change
20th May 20132:20 pmRNSDirector/PDMR Shareholding
20th May 20137:00 amRNSResults for the year ended 31 March 2013
25th Apr 20133:58 pmRNSNotification of Major Interest in Shares
22nd Apr 20135:00 pmRNSNotification of Major Interest in Shares
16th Apr 20137:00 amRNSTrading Statement
9th Apr 201310:00 amRNSTotal Voting Rights
18th Mar 20134:00 pmRNSNotification of Major Interest in Shares
18th Mar 20137:00 amRNSe2v wins ?10m ESA space science contract
6th Mar 20133:11 pmRNSHolding(s) in Company
6th Mar 20132:15 pmRNSHolding(s) in Company
5th Mar 20137:00 amRNSContract Renewal
22nd Feb 20132:02 pmRNSNotification of Major Interest in Shares
14th Feb 201311:00 amRNSDirector/PDMR Shareholding
12th Feb 20134:43 pmRNSDirector/PDMR Shareholding
12th Feb 201311:10 amRNSHolding(s) in Company
11th Feb 20134:13 pmRNSTotal Voting Rights
11th Feb 20137:00 amRNSAppointment of Non-Executive Chairman
31st Jan 20137:00 amRNSInterim Management Statement
8th Jan 201311:40 amRNSTotal Voting Rights
7th Jan 20131:59 pmRNSDirector/PDMR Shareholding
7th Dec 20127:00 amRNSContract Renewal
3rd Dec 20127:00 amRNSSale of land
30th Nov 20123:39 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.